Literature DB >> 21345819

Should a patent foramen ovale found incidentally during isolated coronary surgery be closed?

Tammy T H Lo1, Omar A Jarral, Alex R Shipolini, David J McCormack.   

Abstract

A best evidence topic was written according to a structured protocol. The question addressed was whether incidentally found patent foramen ovale (PFO) during isolated coronary surgery should be closed. A total of 573 papers were found using the reported searches of which six represented the best evidence to answer the clinical question. The authors, date, journal, study type, population, main outcome measures and results are tabulated. There is currently no evidence to suggest that incidental PFO in patients undergoing cardiac surgery is linked with increased morbidity, mortality or decreased long-term survival. The most significant study identified examined the outcomes of 2277 patients with incidentally found PFO during cardiac surgery of whom 639 underwent closure. After propensity matched analysis, the authors found closure was associated with a significantly higher risk of postoperative stroke with no advantage in terms of long-term survival. A recent survey of 438 cardiac surgeons from the USA showed no consensus on decision-making behind closure, but that factors taken in to account include PFO size, right atrial pressure and a history of paradoxical embolism. This is not surprising given that morphological research has confirmed that larger PFO size is indeed associated with cryptogenic stroke.

Entities:  

Mesh:

Year:  2011        PMID: 21345819     DOI: 10.1510/icvts.2011.265835

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  2 in total

1.  Concomitant Left Atrial Myxoma and Patent Foramen Ovale: Is It an Evolutional Synergy for a Cerebrovascular Event?

Authors:  Glenmore Lasam; Roberto Ramirez
Journal:  Cardiol Res       Date:  2017-03-03

2.  Echocardiographic guided, transatrial closure of a patent foramen ovale.

Authors:  Felix Fleissner; Paul Frank; Axel Haverich; Issam Ismail
Journal:  J Cardiothorac Surg       Date:  2020-09-14       Impact factor: 1.637

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.